[Activity studies of an iron-vitamin B6 preparation for euteral treatment of iron deficiency anemia].
In 17 respectively 15 children with iron deficiency anemia the effect of a combined orally applicated iron-vitamin B6 therapy and iron therapy only was studied. Pyridoxal phosphate, activities of pyridoxal kinase and red cell GOT, and excretion of 4-pyridoxic acid in urine were measured as indices of vitamin B6 nutriture before therapy was started, on the 3rd and 6th day with therapy and on the 1st and 4th day after therapy was stopped. Red cells, concentration of hemoglobin, reticulocytes and hematokrit were simultaneously counted, whereas serum iron had been measured once only before therapy. A group of 22 hematologically healthy children was studied as controls. After iron therapy a decrease of vitamin B6 nutriture occured as a consequence of an increased requirement for pyridoxal phosphate for heme synthesis. Additional vitamin B6 was followed by a normal vitamin B6 nutriture and a significantly accelerating effect on heme synthesis.
D000284:Administration, Oral; D000747:Anemia, Hypochromic / Q000188:drug therapy* / Q000378:metabolism; D001219:Aspartate Aminotransferases / Q000097:blood; D002648:Child; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000378:metabolism; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007408:Intestinal Absorption; D007501:Iron / Q000008:administration & dosage* / Q000627:therapeutic use; D011732:Pyridoxal Phosphate / Q000378:metabolism; D011735:Pyridoxic Acid / Q000652:urine; D011736:Pyridoxine / Q000008:administration & dosage* / Q000627:therapeutic use; D012156:Reticulocytes / Q000378:metabolism
D006454:Hemoglobins; D011735:Pyridoxic Acid; D011732:Pyridoxal Phosphate; D007501:Iron; D001219:Aspartate Aminotransferases; D011736:Pyridoxine
Untersuchunger uber die Wirksamkeit eines Eisen-Vitamin B6-Präparates für die enterale Behandlung der Eisenmangelanämie